Topics

Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization

20:00 EDT 2 Aug 2015 | NIH

Scientists at the NIH disclosed a mutated adeno-associated virus (AAV) serotype 5 by modifying sialic acid binding regions which mediate viral entry into host cells. Preliminary results from animal studies suggest that this modification can increase transduction by 3-4 folds in salivary glands and muscles, and can significantly decrease the potential of being neutralized by preexisting antibodies compared to the wild type AAV. Thus, the modified AAV5 vectors seem to be optimal for gene therapy. This invention overcomes two major issues in AAV-based gene therapy: the ability to efficiently transduce the target cells and the ability to evade the immune response to vectors.

IC: 
NHLBI
NIH Ref. No.: 
E-097-2015-0
TAB No: 
TAB-2953
Advantages: 
  • Enhanced transduction activity.
  • Reduced the potential for being neutralized by preexisting antibodies.
Applications: 
  • Genetically engineered AAV5 vectors for gene therapy.
Development Status: 
  • Early-stage
  • In vivo data available (animal)
Provider Technology ID: 
2953
Updated On: 
May 1, 2019
Date Published: 
Monday, August 3, 2015
Patent Application: 
62/143,524
15/092,482
Patent Authority: 
US
US
2016-04-13 00:00:00
2016-04-13 00:00:00
Patent Number: 
10,081,659
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NHLBI
NIDCR
University of Florida
University of Florida
Inventor Lab URL: 
https://irp.nih.gov/pi/john-chiorini
http://msg.mbi.ufl.edu/bio-mavis.html
LPM FIrst Name: 
Vladimir
LPM Last Name: 
Knezevic
LPM Address: 
BG 12A RM 3011 12 SOUTH DR
LPM City: 
Bethesda
Inv Is lead: 
LPM Zip: 
20892
LPM State: 
MD
LPM Phone: 
301.443.5560
LPM Suffix: 
M.D.
LPM Organization: 
NIH Office of Technology Transfer
DTDT Classification: 
Arthritis
Cancer
Diabetes
Endocrine
Therapeutic (biologic)
Gene-based
Early-stage
In vivo data available (animal)
DTDT Description: 
Arthritis
Cancer
Diabetes
Endocrine
Therapeutic (biologic)
Gene-based
Early-stage
In vivo data available (animal)
Pat Filing Date: 
2015-04-06
2016-04-06
Patent Issue Date: 
2018-09-25
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/25410855
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6468524.PN.&OS=PN/6468524&RS=PN/6468524
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6984517.PN.&OS=PN/6984517&RS=PN/6984517
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7479554.PN.&OS=PN/7479554&RS=PN/7479554
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6855314.PN.&OS=PN/6855314&RS=PN/6855314
Publication Caption: 
PMID 25410855
US Patent 6,468,524
US Patent 6,984,517
US Patent 7,479,554
US Patent 6,855,314
Publication Title: 

Afione S, et al.

Chiorini J, et al.

Chiorini J, et al.

Chiorini J, et al.

Chiorini J, et al.

Application Term: 
Technology Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize modified AAV5 vector for gene therapy. For collaboration opportunities, please contact David Bradley, Ph.D. at bradleyda@nidcr.nih.gov.

Related Patents: 
10,300,095
9,511,103
9,833,519
8,808,684
9,439,979
8,283,151
7,407,801
8,137,960
8,685,722
9,193,769
8,927,269
9,238,800
7,419,817
6,468,524
6,984,517
7,479,554
Related Patent Publish Date: 
1480917600
1442552400
1509426000
1459918800
1431406800
1303275600
1334811600
1395291600
1302843600
1334293200
1389592800
1348549200
1380085200
1426568400
1284094800
1402462800
1114750800
1146459600
1146459600
1346994000
1070604000
1102226400
1102312800
1070517600
1102312800
1161838800
1331013600
1392271200
1053320400
1084856400
1166680800
1416981600
1021611600
1021611600
953704800
896331600
927867600
974786400
1121749200
1412830800
1556254800
Related Patent Application: 

15/368,940

14/858,929

15/798,969

15/027,546

62/160,552

61/477,523

PCT/US12/34268

14/112,790

61/476,168

PCT/US12/33556

14/111,604

61/705,517

PCT/US2013/061587

14/428,929

12/879,142

14/301,973

60/676,604

PCT/US2006/017157

11/912,803

13/607,118

60/527,146

PCT/US2004/040717

11/005,410

60/526,786

PCT/US2004/040825

10/581,228

13/413,321

14/179,951

60/472,066

PCT/US2004/015534

10/557,662

14/554,728

60/381,180

10/166,347

09/532,594

60/087,029

PCT/US99/11958

09/717,789

11/184,380

PCT/US2014/059825

16/396,262

Related Patent Authority: 
US
US
US
US
US
US
PCT
US
US
PCT
US
US
PCT
US
US
US
US
PCT
US
US
US
PCT
US
US
PCT
US
US
US
US
PCT
US
US
US
US
US
US
PCT
US
US
PCT
US
Related Invention: 
E-127-1998-0
E-071-2000-0
E-308-2001-0
E-105-2003-0
E-329-2003-0
E-227-2004-0
E-179-2005-0
E-194-2010-0
E-087-2011-0
E-142-2011-0
E-232-2011-1
E-736-2013-1
E-175-2015-0
E Number Only: 
E-097-2015
Inventor First Name: 
John
Sandra
Mavis
Sujata
Inventor Last Name: 
Chiorini
Afione-Wainer
Agbandje-Mckenna
Halder

Original Article: Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization

NEXT ARTICLE

More From BioPortfolio on "Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...